Bariatric Fundus Embolization Viable for Severely Obese Patients
By HospiMedica International staff writers Posted on 17 Apr 2019 |
Image: Dr. Aaron Fischman performing a bariatric embolization procedure (Photo courtesy of Mount Sinai Hospital).
Transarterial embolization of the gastric fundus in severely obese adults can suppress appetite and induce weight loss for up to 12 months, claims a new study.
Researchers at Johns Hopkins University (JHU; Baltimore, MD, USA), Mount Sinai Hospital (New York, NY, USA), and other institutions conducted a prospective study that recruited 20 severely obese adults (16 women; mean age 44 years) with a mean body mass index (BMI) of 45 kg/m2 to evaluate the safety and efficacy of bariatric embolization, an image-guided procedure that aims to induce metabolic changes by targeting the endocrine functions of the gastric fundus, which play a role in stimulating appetite.
Bariatric embolization was performed successfully in all participants, with no major adverse events. The mean excess weight loss was 8.2% at one month, 11.5% at three months, 12.8% at six months, and 11.5% at 12 months. Hunger or appetite decreased for four weeks after embolization, increasing again thereafter, but without reaching pre-embolization levels. Study participants also showed evidence of metabolic change, with decreases in hemoglobin A1c and total cholesterol (independent of weight loss), and concomitant increase in high-density lipoprotein (HDL) levels. The study was published on April 2, 2019, in Radiology.
“Weight loss of 5-10% has been found to reduce risks of cardiovascular disease and diabetes, including reduced hemoglobin A1c, increased HDL, reduced triglycerides, reduced blood pressure, and reduced need for diabetes and antihypertensive medications,” concluded lead author Clifford Weiss, MD, of JHU, and colleagues. “The changes in hemoglobin A1c, and the fact that they occurred independent of weight loss, may indicate that bariatric embolization alters the metabolic profile in ways similar to bariatric surgery, but to a lesser degree.”
Transarterial bariatric embolization of the gastric fundus delivers embolic microspheres into the gastric arteries to induce localized ischemia and modify appetite hormones, leading to weight reduction; early clinical trials have produced promising short-term results in animal models.
Related Links:
Johns Hopkins University
Mount Sinai Hospital
Researchers at Johns Hopkins University (JHU; Baltimore, MD, USA), Mount Sinai Hospital (New York, NY, USA), and other institutions conducted a prospective study that recruited 20 severely obese adults (16 women; mean age 44 years) with a mean body mass index (BMI) of 45 kg/m2 to evaluate the safety and efficacy of bariatric embolization, an image-guided procedure that aims to induce metabolic changes by targeting the endocrine functions of the gastric fundus, which play a role in stimulating appetite.
Bariatric embolization was performed successfully in all participants, with no major adverse events. The mean excess weight loss was 8.2% at one month, 11.5% at three months, 12.8% at six months, and 11.5% at 12 months. Hunger or appetite decreased for four weeks after embolization, increasing again thereafter, but without reaching pre-embolization levels. Study participants also showed evidence of metabolic change, with decreases in hemoglobin A1c and total cholesterol (independent of weight loss), and concomitant increase in high-density lipoprotein (HDL) levels. The study was published on April 2, 2019, in Radiology.
“Weight loss of 5-10% has been found to reduce risks of cardiovascular disease and diabetes, including reduced hemoglobin A1c, increased HDL, reduced triglycerides, reduced blood pressure, and reduced need for diabetes and antihypertensive medications,” concluded lead author Clifford Weiss, MD, of JHU, and colleagues. “The changes in hemoglobin A1c, and the fact that they occurred independent of weight loss, may indicate that bariatric embolization alters the metabolic profile in ways similar to bariatric surgery, but to a lesser degree.”
Transarterial bariatric embolization of the gastric fundus delivers embolic microspheres into the gastric arteries to induce localized ischemia and modify appetite hormones, leading to weight reduction; early clinical trials have produced promising short-term results in animal models.
Related Links:
Johns Hopkins University
Mount Sinai Hospital
Latest Surgical Techniques News
- Miniaturized Implantable Multi-Sensors Device to Monitor Vessels Health
- Tiny Robots Made Out Of Carbon Could Conduct Colonoscopy, Pelvic Exam or Blood Test
- Miniaturized Ultrasonic Scalpel Enables Faster and Safer Robotic-Assisted Surgery
- AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy Detects More Lesions
- First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing
- Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery